Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256044 | 0.91 | SMPD1 (0.59) | SMPD1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL3604210 | 0.89 | MAOB (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29475634 | 0.87 | LMNA (0.69) | SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL90412 | 0.87 | LMNA (0.69) | SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12221470 | 0.86 | NPC1 (0.57) | SMPD1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL9071285 | 0.85 | SMPD1 (0.56) | SMPD1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL8663810 | 0.85 | LMNA (0.59) | SMPD1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL13413526 | 0.84 | SMN1; SMN2 (0.54) | SMPD1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL3729907 | 0.83 | NPC1 (0.75) | RAB9ANPC1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2254423 | 0.83 | SMPD1 (0.76) | SMPD1RAB9ANPC1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | SMPD1 1893/4885RAB9A 1193/4885NPC1 3660/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | SMPD1 2594/4885RAB9A 1081/4885NPC1 3229/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | SMPD1 2622/4885RAB9A 982/4885NPC1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.